Диссертация (Пути преодоления фармакорезистентности при лечении артериальной гипертензии), страница 41

26. –n. 9. –P. 943–954.209. Sullivan G.W., Carper H.T., Novick W.J., Mandell G.L. Inhibition ofthe inflammatory action of interleukin-1 and tumor necrosis factor (alpha)on neutrophil function by pentoxifylline. // Infect. Immunol. -1988. -Vol. 56.-P. 1722–1729.210. Szabo B., Bock C., Nordheim U. Mechnism of the sympaticoinhibition produced by the clonidine-like drags rilmenidine and moxonidine. //Ann. NY. Acad. Sci.

-1999. -Vol. 881. -P. 253-264.211. Tiano L., Belardinelli R. et al. Effect of coenzyme Q10 administrationon endothelial function and extracellular superoxide dismutase in patientswith ischaemic heart disease: a double-blind, randomized controlled study. //Europ.Heart J. -2007. -Vol. 28.

-P. 2249–2255.255212. Tobe S.W., Lewanczuk R. Resistant hypertension. // Can. J. Cardiol.-2009. -Vol. 25. –n. 5. -P. 315–317.213. Torre-Amione G., Stetson S.S., Farmer J.A. Clinical implications oftumor necrosis facror a antagonist in patientswith congestive heart failure. //Ann. Rheum. Dis. -1999. -Vol. 58 (Suppl 1). -P.1103-1106.214. Trewet C.L.B., Ernst M.E. Resistant Hypertension: Identifying Causes and Optimizing Treatment Regimens // Medical Journal. -2008. -Vol.101.–n. 2. -P. 118-112.215.

Van Zwielon P. Central imidazoline (I-1) receptors as targets of centrally acting antihypertensives. Clinical pharmacology of Moxonidine andrilmonidine. // Ann. NY Acad. Sci. -1999. -Vol. 881. -P. 420-429.216. Vidt D.G. Contributing factors in resistant hypertension: Truly refractory disease is rarely found in a properly conducted workup. // Postgrad.Med. –2000.

-May I. –Vol. 107. –P. 5.217. Viera A.J., Hinderliter A.L. Evaluation and management of the patientwith difficult-to-control or resistant hypertension. // American Family Physician. -2009. –Vol. 79. –n. 10. -P. 863–869.218. Waage A., Sorensen M., Stordal B. Differential effect of oxpentifylline on tumour necrosis factor and interleukin-6 production. // Lancet.

-1990.–Vol. 335. -P. 543.219. Wallukat G., Bochnig N., Homuth V. Agonistic AT1 receptor autoantibodies and monocyte stimulation in hypertensive patients. // Am. J. Hypertens. -2003. –Vol. 16. –n. 10. –P. 827–833.220. Weinberger M.H. Salt-sensitivity of blood pressure in humans. //Hypertension. -1996.

-Vol. 27 (Рart. 2). –P. 481-490.221. Wenzel К., Haase Н., Wallukat G. (2008) Potential relevance of a1adrenergic receptor autoantibodies in refractory hypertension. // PLoS ONE.-2008. –Vol. 3. –n. 11. –P. 37-42.222. Wexberg Р., Gyongyosi M., Sperker W. Pre-existing arterial remodel-256ing is associated with in-hospital and late adverse cardiac events after coronary interventions in patients with stable angina pectoris.

// J. Am. Coll.Cardiol. -2009. –Vol. 36. –n. 6. –P. 1860–1869.223. Whelton P.K., He J., Appel L.J., Cutler J.A., Havas S., Kotchen T.A.Primary prevention of hypertension: Clinical and public health advisoryfrom The National High Blood Pressure Education Program. // JAMA.-2002. -Vol. 288. –n.

15. -P. 1882–1888.224. Yamagami T., Takagi M., Akagami H., Kubo H., Toyama S., Okamoto T. Effect of Coenzyme Q10 on essential hypertension: a double blind control study. // Elsvier. -1986. –P. 337–343.225. Zhu F., Sun Y., Liao Y. Agonistic AT1 receptor autoantibody increases in serum of patients with refractory hypertension and improves Ca2+ mobilization in cultured rat vascular smooth muscle cells. // Cell. Mol.Immunol. -2008. –Vol. 5.

–n. 3. –P. 209–217.226. Zieman S.J., Melenovsky V., Kass D.A. "Mechanisms, pathophysiology, and therapy of arterial stiffness". // Arterioscler. Thromb. Vasc. Biol.-2005. -Vol. 25. –n. 5. -P. 932–943.227. Blumenthal J.A., Babyak M.A., Hinderliter A. Effects of the DASH dietalone and in combination with exercise and weight loss on blood pressure andcardiovascular biomarkers in men and women with high blood pressure: theENCORE study.

// Arch. Intern. Med. -2010. –Vol. 170. –n. 2. -P. 126–35.228. Brown M.A., Buddle M.L., Martin A. Is resistant hypertension really resistant? // Am. J. Hypertens. -2001. –Vol. 14. –n.12. –P. 1263-1269.229. Dantzer R., Konsman J.P., Bluthe R.M., Kelley K.W. Neural and humoral pathways of communication from the immune system to the brain: parallel or convergent. // Auton. Neursci. –2009. –Vol.

85. –n. 1. –P. 60–65.230. Din-Dzietham R., Liu Y., Bielo M.V., Shamsa F. High blood pressuretrends in children and adolescents in national surveys, 1963 to 2002. // Circulation. -2007. -Vol. 116. –n. 13. -P. 1488–1496.257231. Ehret G.B., Munroe P.B., Rice K.M. Genetic variants in novel pathwaysinfluence blood pressure and cardiovascular disease risk // Nature. -2011.-Vol.478. –n. 7367.

-P. 103–109.232. Esler M., Lambert E., Schlaich M. Point: Chronic activation of thesympathetic nervous system is the dominant contributor to systemic hypertension. // J. Appl. Physiol. -2010. –Vol. 109. –n. 6. –P. 1996–1998.233. Franklin, S.S., Wilkinson I.B., McEniery C.M. Unusual hypertensivephenotypes: what is their significance? // Hypertension. -2012.

-Vol. 59.–n. 2.-P. 173–178.234. Gautron L., Lafon P., Chaigniau M., Tramu G., Laye S. Spatiotemporalanalysis of signal transducer and activator of transcription 3 activation in ratbrain astrocytes and pituitary following peripheral immune challenge.

// Neuroscience. –2009. –Vol. 112. n. 4. –P. 717–729.235. Grossman E., Messerli F.H. Drug-induced Hypertension: An Unappreciated Cause of Secondary Hypertension. // Am. J. Med. -2012. –Vol. 125.–n. 1. -P. 14–22.236. Klarenbach S.W., McAlister F.A., Johansen H., Tu K., Canadian Hypertension Education, Program. Identification of factors driving differences incost effectiveness of first-line pharmacological therapy for uncomplicated hypertension. // The Canadian journal of cardiology . -2010.

–Vol. 26.–n. 5. –e158–63.237. Konsman J.P., Parnet P., Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications. // Trends Neurosci. –2007. –Vol. 25.–n. 1. –P. 154–159.238. Kotchen T.A. Historical trends and milestones in hypertension research:a model of the process of translational research. // Hypertension. -2011.–Vol. 58. –n.

4. –P. 522–538.258239. Maes M. Major depression and the activation of the inflammatory response system. // Adv. Exp. Med. Biol. –2009. –Vol. 46. –n. 111. –P. 25–46.240. Marchesi C., Paradis P., Schiffrin E.L. Role of the renin-angiotensin system in vascular inflammation // Trends Pharmacol. Sci. -2008. –Vol. 29.–n. 7.

-P. 367–374.241. Marshall I.J., Wolfe C.D., McKevitt C. Lay perspectives on hypertension and drug adherence: systematic review of qualitative research. // BMJ. 2012. –Vol. 345. –e. 3953.242. Muxfeldt E.S., Fiszman R., de Souza F., Viegas B., Oliveira F.C., SallesG.F.

Appropriate time interval to repeat ambulatory blood pressure monitoringin patients with white-coat resistant hypertension. // Hypertension.-2012. -Vol.59. –n. 2. –P. 384-389.243. National Institute Clinical Excellence. Initiating and monitoring antihypertensive drug treatment, including blood pressure targets". Hypertension:Clinical management of primary hypertension in adults.244.

Ostchega Y., Dillon C.F., Hughes J.P., Carroll M., Yoon S. Trends inhypertension prevalence, awareness, treatment, and control in older U.S.adults: data from the National Health and Nutrition Examination Survey 1988to 2004. // Journal of the American Geriatrics Society. -2007.–Vol. 55. –n. 7. –P. 56–65.245. Palatini P., Julius S.

The role of cardiac autonomic function in hypertension and cardiovascular disease. // Curr. Hypertens. Rep. -2009. –Vol. 11.–n. 3. -P. 199–205.246. Rainforth M.V., Schneider R.H., Nidich S.I. Stress Reduction Programsin Patients with Elevated Blood Pressure: A Systematic Review and Metaanalysis. // Curr. Hypertens. Rep. -2007. –Vol. 9. –n. 6. –P. 520–528.259247. Tamimi N.A. Resistant hypertension: a methodological approach to diagnosis and treatment. // Saudi J. Kidney Dis. Transplant. -2007. –Vol. 18.–n. 3. –P.

337–345.248. Ting H.H., Timimi F.K., Haley E.A., Roddy M.A. Vitamin С improvesendothelium-dependent vasodilation in forearm vessels of humans with hypercholes-terolemia. // Circulation. -1997. -Vol. 95. -P. 2617-2622.249. Veglio F., Rabbia F., Riva P., Martini G. Ambulatory blood pressuremonitoring and clinical characteristics of the true and white-coat resistant hypertension.

// Clin. Exp. Hypertens. -2001. –Vol. 23. –n. 3. –P. 203-211.250. Versari D., Daghini E., Virdis A., Ghiadoni L., Taddei S. Endotheliumdependent contractions and endothelial dysfunction in human hypertension. //Br. J. Pharmacol.

-2009. –Vol. 157. –n. 4. -P. 527–536..